Cancer Research Program, The Garvan Institute of Medical Research, 384 Victoria St., Darlinghurst, New South Wales 2010, Australia.
Cancer Lett. 2012 May 1;318(1):76-85. doi: 10.1016/j.canlet.2011.12.003. Epub 2011 Dec 9.
To identify epigenetic-based biomarkers for diagnosis of ovarian cancer we performed MeDIP-Chip in A2780 and CaOV3 ovarian cancer cell lines. Validation by Sequenom massARRAY methylation analysis confirmed a panel of six gene promoters (ARMCX1, ICAM4, LOC134466, PEG3, PYCARD & SGNE1) where hypermethylation discriminated 27 serous ovarian cancer clinical samples versus 12 normal ovarian surface epithelial cells (OSE) (ROC of 0.98). Notably, CpG sites across the transcription start site of a potential long-intergenic non-coding RNA (lincRNA) gene (LOC134466), was shown to be hypermethylated in 81% of serous EOC and could differentiate tumours from OSE (p<0.05). We propose that this potential biomarker panel holds great promise as a diagnostic test for high-grade (Type II) serous ovarian cancer.
为了鉴定用于卵巢癌诊断的基于表观遗传学的生物标志物，我们在 A2780 和 CaOV3 卵巢癌细胞系中进行了 MeDIP-Chip 实验。通过 Sequenom 质谱甲基化分析进行验证，证实了一组六个基因启动子（ARMCX1、ICAM4、LOC134466、PEG3、PYCARD 和 SGNE1），其甲基化程度可区分 27 例浆液性卵巢癌临床样本与 12 例正常卵巢表面上皮细胞（OSE）（ROC 为 0.98）。值得注意的是，在潜在的长基因间非编码 RNA（lincRNA）基因（LOC134466）转录起始位点的 CpG 位点在 81%的浆液性 EOC 中被高度甲基化，可区分肿瘤与 OSE（p<0.05）。我们提出，该潜在的生物标志物组合有望成为高级别（II 型）浆液性卵巢癌的诊断测试。
